C & O Pharmaceutical Technology (Holdings) Limited engages in the research and development, manufacture, marketing, and distribution of branded and third party pharmaceutical products primarily in China. The company offers anti-infection and gastrointestinal drugs, drugs for ageing adults, and specialized drugs. Its products are used for various indications, such as skin soft tissues infections, analgesic and antipyretic, indigestion or gastro esophageal reflux disorder, respiratory tract infections, otitis media, sinusitis, acute pharyngitis, UTI, hypertension, migraine, pancreatitis, upper gastrointestinal hemorrhage, pancreatic fistula, intestinal fistula, biliary fistula, breast cancer, ...
911-12 Silvercord Tower 2
30 Canton Road
Tsim Sha Tsui,
Founded in 2003
C & O Pharmaceutical Technology (Holdings) Limited Launches First Rabeprazole Sodium for Injection
Sep 29 14
Shionogi & Co. Ltd. announced that its subsidiary C & O Pharmaceutical Technology (Holdings) Limited launched the first Rabeprazole Sodium for Injection (®) in China, on September 29 2014, which was developed by C&O itself. Proton-pump inhibitors (PPIs) inhibit gastric acid secretion by blocking the final stage of gastric acid secretion. ®, developed by C&O, belongs to the second generation of proton pump inhibitors and it is the only injectable rabeprazole product for the treatment of peptic ulcer in China. ® shows a rapid and long lasting gastric antisecretory activity and not easily metabolized by human drug metabolizing enzymes such as cytochrome P450s. Its clinical studies demonstrated that there is less concern for individual differences in efficacy and drug-drug interactions. The launch of ® that has the rapid and long lasting acid suppression activity is expected to contribute to the treatment of peptic ulcer in China by satisfying the unmet medical need of patients and healthcare providers as a new treatment option for gastric or duodenal ulcer which cannot accept oral treatment due to bleeding.